Quote:Donald Trump gets claim about U.S. GDP doubly wrong
By Louis Jacobson on Tuesday, June 16th, 2015 at 4:11 p.m.
During his rambling presidential announcement speech, real estate developer and television personality Donald Trump took on many, many targets. One of those was economic growth under President Barack Obama.
"The last quarter, it was just announced, our gross domestic product -- a sign of strength, right? But not for us. It was below zero. Who ever heard of this? It's never below zero."
For starters, Trump didn’t even phrase his claim correctly. He said that "our gross domestic product … was below zero." Real gross domestic product was in the trillions of dollars -- not anywhere close to zero. He meant growth in GDP. But even phrased appropriately, his claim is wrong.
(Trump's staff did not return inquiries from PolitiFact.)
The real annualized change in gross domestic product during the first quarter of 2015 was indeed negative -- it fell by 0.7 percent. But "never below zero"? That’s way off.
Negative GDP growth -- in other words, GDP shrinkage -- from quarter to quarter is one of the hallmarks of a recession. And there have been lots of recessions over the years -- 11 since World War II.
The first year the government calculated the change in GDP from quarter to quarter was 1947.
We looked back and found no fewer than 42 quarters over that period in which GDP shrank on an annualized, seasonally adjusted basis. That’s roughly 15 percent of the time.
Here’s a summary of how frequently this has happened historically:
Year Quarters of negative GDP growth that year
1947 2
1949 3
1953 2
1954 1
1956 2
1957 2
1958 1
1959 1
1960 2
1969 1
1970 2
1973 1
1974 3
1975 1
1980 2
1981 2
1982 2
1990 1
1991 1
2001 2
2008 3
2009 2
2011 1
2014 1
2015 1
We should also note that the poor first quarter of 2015 may not end up as a negative quarter once the final revisions are made. In a couple of weeks, the government will release a final number that takes into account new and complete data, and it’s currently so close to zero that it’s possible it could slip into positive territory.
It’s also worth noting that this quarterly figure should be taken with some caution.
"This estimate does not suggest a recession," said Tara Sinclair, an economist with George Washington University. "We've had a weird pattern in the last few years of weak first quarter estimates." Some analysts have chalked these up to unusually harsh winters that seasonal adjustments weren’t strong enough to iron out. The general rule of thumb is that it takes two quarters of negative growth to signal a recession.
Finally, since Trump was attacking Obama for this bad quarter of growth, we’ll just throw this out: Of the 42 quarters of negative growth since World War II, 30 occurred under Republican presidents and just 12 under Democratic presidents.
Our ruling
Trump said that in "the last quarter, it was just announced, our gross domestic product … was below zero. Who ever heard of this? It's never below zero." He messes up his economic terms; the gross domestic product was not "zero." And the growth in the gross domestic product has been below zero 42 times over 68 years.
That’s a lot more than "never." We rate his claim Pants on Fire!
Trump, F.O.S on this subject when this was written and F.
Top 10 Most Recent News Articles
World Young Scientist Summit 2026 in Wenzhou Kicks Off
Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...
Continue Reading
Aluminum Design Fumble: Geometry Over Wall Thickness
A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...
Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety
Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...
Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial
Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...
Continue Reading
What to Expect: Your First Therapy Session Insights
Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...
Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study
Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...
Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC
New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...
Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC
Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...
Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians
Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...
Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese
Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...
Continue ReadingTop 5 Most Recently Viewed Articles
NVIDIA and Synopsys Forge Alliance to Transform Engineering
Strategic Collaboration Between NVIDIA and Synopsys In an exciting development for the engineering and design industries, NVIDIA and Synopsys have joined forces in a strategic partnership that promises to revolutionize how these sectors operate. This collaboration aims to leverage NVIDIA's powerful computational capabilities alongside Synopsys' sophisticated engineering...
Continue Reading
EHang's Groundbreaking Pilotless Flight Marks a Historic Event
EHang's Historic Pilotless Flight in Africa EHang Holdings Limited (Nasdaq: EH), a frontrunner in Urban Air Mobility (UAM), has made headlines by achieving a remarkable milestone: the first pilotless human-carrying flight of its EH216-S eVTOL aircraft in Africa. This significant event unfolded at the 9th Aviation Africa Summit in Kigali, marking a historic moment for the...
Continue Reading
Bang & Olufsen's Share Buyback: Strategic Moves for Growth
Understanding Bang & Olufsen's Share Buyback Program Bang & Olufsen A/S has embarked on a significant initiative aimed at bolstering its long-term growth through its recent share buyback program. This strategic move is designed to hedge the company’s share-based long-term incentive programmes, showcasing their commitment to enhancing shareholder value. This article...
Continue Reading
Johnson & Johnson's Q2 Expectations and Analyst Ratings Insights
Upcoming Earnings Announcement for Johnson & Johnson Johnson & Johnson (NYSE: JNJ) is preparing to disclose its earnings results for the upcoming second quarter. Analysts are closely watching the anticipated report, which is expected to provide valuable insights into the company's financial health. Expected Financial Performance Analyst forecasts suggest that Johnson &...
Continue Reading
Safe House Project Expands Impact with ATI Acquisition
Safe House Project Expands Impact with ATI Acquisition This Giving Tuesday, the Safe House Project (SHP) shared exciting news about its acquisition of Anti-Trafficking International (ATI), an organization that has been pivotal in the fight against human trafficking. By incorporating ATI's respected practices and its renowned Just Ask Prevention Curriculum, SHP aims to...
Continue Reading